Trial Profile

A Phase 2 Clinical Trial of Renaparin to Prevent Ischemia/Reperfusion Injury (IRI) in Kidney Transplantation

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Sep 2023 According to Corline Biomedical media release, the company received approval to conduct study in England.
29 Aug 2023 According to Corline Biomedical media release, Germanys health care authority BfArM approves the start of the phase 2 study RENAPAIR 02 in accordance with the application submitted by the Company. This trial will be carried out in 15 clinics in the UK, Germany and Austria, In connection with the BrArM approval, Corline also obtained approvals from local ethics committees in Austria and Germany. Thus, Corline now has the permissions required to recruit patients in RENAPAIR 02.
29 Aug 2023 Status changed from planning to not yet recruiting as Corline Biomedical media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com